Back to search
FDAFDA · Food and drugs·Recall number Z-0718-2021

APEX Compounding System Control Panel Module, REF: 601237, Product Code AX1000 - Product Usage: intended for intravascular administration to a patient.

Published December 30, 2020 · Recall initiated: November 23, 2020

Summary

FDA records medical device Class II recall Z-0718-2021, published December 30, 2020 and initiated November 23, 2020. Recalling firm: B Braun Medical, Inc.; Status: Terminated; Reported quantity: 85 units; Lot: All APEX Compounding System with Software Version 1.0.5.57 or earlier. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

There is the potential for the compounding system to not immediately interrupt compounding and alert user to the presence of an air bubble exceeding 3% of the ordered volume for an ingredient. This could result in a a compounded drug that does not meet the specified accuracy range for an individual ingredient.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
B Braun Medical, Inc.
Distributor
US Nationwide distribution including in the states of AL, AZ, CA, CO, CT, FL, GA, IA, IL, LA, MA, MD, MI, MN, MO, NC, NH, NJ, NV, NY, OH, OK, PA, TN,TX, WA.
Lot
All APEX Compounding System with Software Version 1.0.5.57 or earlier
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was APEX Compounding System Control Panel Module, REF: 601237, Product Code AX1000 - Product Usage: intended for intravascular administration to a patient. recalled?

Yes. FDA published recall Z-0718-2021 on December 30, 2020. Reported hazard: There is the potential for the compounding system to not immediately interrupt compounding and alert user to the presence of an air bubble exceeding 3% of the ordered volume for an ingredient. This could result in a a compounded drug that does not meet the specified accuracy range for an individual ingredient.

What should I do if I have this product?

Voluntary: Firm initiated · Letter